Skip to main content
. 2020 Mar 8;8(1):e000260. doi: 10.1136/jitc-2019-000260

Table 2.

Symptom burden (PRO-CTCAE) by time since last checkpoint inhibitor dose

Frequency % reporting
Overall (n=90) <24 months (n=37) 24 to <36 months (n=27) 36+months (n=26) P value
Frequently/
almost constantly
Occasionally Frequently/almost constantly Occasionally Frequently/almost constantly Occasionally Frequently/almost Constantly
Aching muscles 12 22 3 22 22 12 15 0.11
Aching joints 17 24 14 22 19 12 19 0.74
Headache 6 11 8 19 7 19 0 0.56
Vision problems* 3 3 0 30 0 4 12 <0.01
Fever† 0 0 0 0 0 0 0 --
Severity Severe/very severe Moderate Severe/
very severe
Moderate Severe/
very severe
Moderate Severe/
very severe
Aching muscles 10 28 0 20 15 29 14 0.50
Aching joints 4 37 0 26 0 33 13 0.35
Headache 7 41 6 29 7 33 8 0.98
Itchy skin‡ 9 16 14 22 7 4 4 0.18
Numbness/tingling§ 11 0 5 4 19 4 12 0.23
Interference with daily activities Quite a bit/Very much Somewhat Quite a bit/very much Somewhat Quite a bit/very much Somewhat Quite a bit/very much
Aching muscles 6 11 0 20 5 14 14 0.54
Aching joints 9 16 5 26 0 7 27 0.10
Headache 2 12 0 14 7 8 0 0.89
Numbness/tingling 9 0 0 27 18 11 11 0.05

*Only frequency is available for vision problems in the PRO-CTCAE.

†Only frequency is available for fever in the PRO-CTCAE.

‡Only severity of itchy skin is included in the PRO-CTCAE.

§Only severity and interference of numbness/tingling is included in the PRO-CTCAE.

PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Event.